177 related articles for article (PubMed ID: 25424920)
21. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
Front Immunol; 2020; 11():585768. PubMed ID: 33193410
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
[TBL] [Abstract][Full Text] [Related]
24. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
[TBL] [Abstract][Full Text] [Related]
25. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
26. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
28. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.
Quang C; Chung AW; Kemp TJ; Ratu T; Tuivaga E; Russell FM; Licciardi PV; Toh ZQ
J Med Virol; 2024 Jun; 96(6):e29732. PubMed ID: 38874202
[TBL] [Abstract][Full Text] [Related]
29. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
[TBL] [Abstract][Full Text] [Related]
30. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.
Ferguson M; Heath A; Johnes S; Pagliusi S; Dillner J;
Int J Cancer; 2006 Mar; 118(6):1508-14. PubMed ID: 16184553
[TBL] [Abstract][Full Text] [Related]
31. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
[TBL] [Abstract][Full Text] [Related]
32. Description of a novel multiplex avidity assay for evaluating HPV antibodies.
Brady AM; Unger ER; Panicker G
J Immunol Methods; 2017 Aug; 447():31-36. PubMed ID: 28433580
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
34. The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus.
Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
Hum Vaccin Immunother; 2018; 14(9):2318-2322. PubMed ID: 29708835
[TBL] [Abstract][Full Text] [Related]
35. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731
[TBL] [Abstract][Full Text] [Related]
36. Multiplex immunoassay to measure antibody response to nine HPV vaccine types.
Panicker G; Rajbhandari I; Pathak HN; Brady AM; Unger ER
J Immunol Methods; 2021 Nov; 498():113136. PubMed ID: 34464605
[TBL] [Abstract][Full Text] [Related]
37. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
38. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine.
Pattyn J; Panicker G; Willhauck-Fleckenstein M; Van Keer S; Téblick L; Pieters Z; Tjalma WAA; Matheeussen V; Van Damme P; Waterboer T; Unger ER; Vorsters A
J Med Virol; 2020 Dec; 92(12):3774-3783. PubMed ID: 32266996
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
[TBL] [Abstract][Full Text] [Related]
40. Development of a 2-plex luminex-based competitive immunoassay to quantify neutralizing antibodies induced by virus-like particles for human papillomavirus 16 and 18.
Lv P; Zhu H; Wang H; Wang G
J Biomed Biotechnol; 2011; 2011():272806. PubMed ID: 21808597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
